DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0190248 A1 Himmelsbach Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 2011 0190248A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0190248 A1 Himmelsbach et al. (43) Pub. Date: Aug. 4, 2011 (54) CYCLOHEXYLOXY SUBSTITUTED A6IP 29/00 (2006.01) HETEROCYCLES, PHARMACEUTICAL A6IP37/08 (2006.01) COMPOSITIONS CONTAINING THESE A6IP II/00 (2006.01) COMPOUNDS AND PROCESSES FOR A6IP II/06 (2006.01) PREPARING THEMI A6IP II/4 (2006.01) A6IP35/00 (2006.01) (75) Inventors: Frank Himmelsbach, 52) U.S. C S14/171: 514/252.17:544,293 Mittelbiberach (DE); Birgit Jung, (52) U.S. Cl. ..................... s • s Laupheim (DE); Ralf Lotz, (57) ABSTRACT Schemmerhofen (DE) The present invention relates to cyclohexyloxy-substituted (73) Assignee: Boehringer Ingelheim heterocycles of general formula (I) International GmbH, Ingelheim am Rhein (DE) (I) (21) Appl. No.: 13/057,872 R NN1 H (22) PCT Filed: Jul. 23, 2009 O (86). PCT No.: PCT/EP2009/059510 s O l N2 Rd N1 Rb, S371 (c)(1), (2), (4) Date: Mar. 21, 2011 N-A (30) Foreign Application Priority Data the tautomers, the stereoisomers, the mixtures thereof and the Aug. 8, 2008 (EP) .................................. O8104995.9 salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable Publication Classification pharmacological properties, particularly an inhibitory effect (51) Int. Cl. on signal transduction mediated by tyrosine kinases, the use A 6LX 3/57 (2006.01) thereof for the treatment of diseases, particularly tumoral A6 IK3I/56 (2006.01) diseases as well as benign prostatic hyperplasia (BPH), dis CO7D 403/2 (2006.01) eases of the lungs and airways and the preparation thereof. US 2011/O 190248 A1 Aug. 4, 2011 CYCLOHEXYLOXY SUBSTITUTED 0007 or HETEROCYCLES, PHARMACEUTICAL 0008 a group selected from among COMPOSITIONS CONTAINING THESE 0009 C-alkyl, C-alkyl-O, C-alkenyl, C COMPOUNDS AND PROCESSES FOR alkynyl, phenyl, phenyl-O, phenyl-C-alkyl- and PREPARING THEMI phenyl-C-alkyl-O, heteroaryl, heteroaryl-O. heteroaryl-C-alkyl and heteroaryl-C-alkyl-O. while the above-mentioned phenyl groups are mono- or disubstituted by R groups, 0001. The present invention relates to cyclohexyloxy-sub 0010 and stituted heterocycles of general formula I0011 R denotes hydrogen, 0012 or 0013 a group selected from among (I) R H 0014 F, Cl, Brand CH, NN1 I0015I R' denotes hydrogen, oran optionally substituted group selected from among C-alkyl, C-cycloalkyl O and C-e-cycloalkyl-C-alkyl, s O 0016 R denotes hydrogen, oran optionally substituted l 2 Rb, group selected from among C-alkyl, C-cycloalkyl, N Rd N1 C-cycloalkyl-C-alkyl, C-alkyl-CO, C-cy cloalkyl-CO, C-cycloalkyl-C-alkyl-CO, C NHA alkyl-SO, C-cycloalkyl-SO, C-cycloalkyl-C- alkyl-SO, phenyl-CO—and phenyl-SO, 10017 R denotes hydrogen or the tautomers, the stereoisomers, the mixtures thereof and the 0018 a group selected from among salts thereof, particularly the physiologically acceptable salts 0019 F, Cl, Br, I, OH, C-alkyl, C-alkyl-O, C thereof with inorganic or organic acids, which have valuable alkyl-O substituted by 1 to 3 fluorine atoms, C.- pharmacological properties, particularly an inhibitory effect cycloalkyl-O, C-7-cycloalkyl-C-alkyl-O, tetrahy on signal transduction mediated by tyrosine kinases, the use drofuran-3-yl-O, tetrahydropyran-3-yl-O. thereof for the treatment of diseases, particularly tumoral tetrahydro-pyran-4-yl-O, tetrahydrofuranyl-C- diseases as well as benign prostatic hyperplasia (BPH), dis alkyl-O and tetrahydropyranyl-C-alkyl-O. eases of the lungs and airways and the preparation thereof. 0020 or 0002 The problem of the present invention is to prepare (0021) R' C-alkyl, wherein the linking of the new compounds which on the basis of their pharmaceutical groups R* may take place via each Catom of the alkyl effectiveness as tyrosine-kinase inhibitors, may be used grOup, therapeutically, i.e. for the treatment of pathophysiological 0022 or processes caused by hyperfunction of tyrosine kinases. (0023) R' C-alkyl-O, wherein the group R is separated from the oxygenatom by at least2C atoms, DETAILED DESCRIPTION OF THE INVENTION 0024 or 0025 a group selected from among 0003. It has surprisingly been found that the problem men 0026 pyrrolidin-2-yl-C-alkyl-O, pyrrolidin-3-yl tioned above is solved by compounds of formula (I), wherein C-alkyl-O, piperidin-2-yl-Ca-alkyl-O, piperidin the groups R* to R and A have the meanings given hereinaf 3-yl-C-alkyl-O, piperidin-4-yl-Ca-alkyl-O, ter. The present invention therefore relates to compounds of aZepan-2-yl-C-alkyl-O. azepan-3-yl-C-alkyl-O. general formula (I), aZepan-4-yl-C-alkyl-O. morpholin-2-yl-Ca alkyl-O, morpholin-3-yl-C-alkyl-O. 1-(C- alkyl)-pyrrolidin-2-yl-Ca-alkyl-O. 1-(C-alkyl)- (I) pyrrolidin-3-yl-C-alkyl-O. 1-(C-alkyl)- RS -H piperidin-2-yl-C-alkyl-O, 1-(C-alkyl)- piperidin-3-yl-C-alkyl-O, 1-(C-alkyl)- piperidin-4-yl-C-alkyl-O. 1-(C-alkyl)-azepan N1 N O O 2-yl-C-alkyl-O. 1-(C-alkyl)-azepan-3-yl-C- alkyl-O. 1-(C-alkyl)-azepan-4-yl-C-alkyl-O. se Rd -R 4-(C-alkyl)-morpholin-2-yl-C-alkyl-O and 4-(C-alkyl)-morpholin-3-yl-C-alkyl-O. RC N-A 0027 wherein 10028) R' denotes a group, which may be identical or different, selected from among wherein 0029 OH, C-alkyl-O, C-cycloalkyl-O, NH, 0004 R* denotes a phenyl or 1-phenylethyl group, C-alkyl-NH. (C-alkyl).N. (2-methoxyethyl) wherein the phenyl nucleus is substituted in each case by N. pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, the groups R' to R, where morpholin-4-yl, 1,4-oxazepan-4-yl, 2-oxa-5-aza 0005) R' and R which may be identical or different, bicyclo[2.2.1]hept-5-yl, 3-oxa-8-aza-bicyclo[3.2. denote hydrogen or a group selected from among 1 oct-8-yl, 8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl, 0006 F, Cl, Br, I, OCHF, OCHF OCF, CHF, piperazin-1-yl 4-(C-alkyl)-piperazin-1-yl, 1,4- CHF, CF, CN, NO, NH, and OH, diazepan-1-yl 4-(C-alkyl)-1,4-diazepan-1-yl, US 2011/O 190248 A1 Aug. 4, 2011 HCO. NH, C-alkyl-CO. NH, C-alkyl-O- tis, cystic fibrosis or mucoviscidosis, alpha-1-antitrypsin C-alkyl-CO. NH, C-alkyl-O CO. NH, deficiency, cough, pulmonary emphysema, interstitial lung HNCONH, C-alkyl-NH CO. NH, (C- diseases, alveolitis, hyperreactive airways, nasal polyps, pull alkyl)-N CONN, pyrrolidin-1-yl-CO. NH, pip monary oedema, pneumonitis of different origins, e.g. radia eridin-1-yl-CO. NH, piperazin-1-yl-CO. NH, tion-induced or caused by aspiration or infectious pneumoni 4-(C-alkyl)-piperazin-1-yl-CO—NH, morpho tis, collagenoses such as lupus erythematodes, systemic lin-4-yl-CO. NH and C-alkyl-SO. NH, Sclerodermy, sarcoidosis and Boeck's disease. while the pyrrolidinyl, piperidinyl, azepan-1-yl, piperazinyl, 0047. It is also particularly preferred to use the compounds 1,4-diazepan-1-yl, morpholinyl and 1,4-oxazepan-4-yl of formula (I) in cases of inflammatory orallergic complaints groups mentioned above in the definition of the group R may in which autoimmune reactions are involved. It is also par each additionally be substituted by one or two C-alkyl ticularly preferred to use the compounds of formula (I) in groups, cases of a disease in the form of benign or malignant tumours. 0030 and 0048. The invention further relates to a pharmaceutical wherein the above-mentioned phenyl groups are mono- or formulation containing a compound of formula (I). disubstituted by groups R, wherein 0049 Preferably an orally administered pharmaceutical I0031. Rdenotes hydrogen, or formulation containing a compound of formula (I) is used. 0032 a group, which may be identical or different, 0050. The invention further relates to medicament combi selected from among F, Cl, Br, I, OH, CN, C-alkyl, nations which contain, besides one or more compounds of C-alkyl-O, CHF, CF - O CHF and formula (I), as further active Substances, one or more com —O—CF, pounds selected from among the categories of betamimetics, 0033 and anticholinergics, corticosteroids, further PDE4-inhibitors, unless stated otherwise, the above-mentioned alkyl groups LTD4-antagonists, EGFR-inhibitors, dopamine agonists, may be straight-chain or branched, H1-antihistamines, PAF-antagonists and PI3-kinase inhibi 0034. A denotes —CO or - C -alkylene, tors or double or triple combinations thereof. 0035 wherein the -C-C-alkylene group may be 0051 Suitable betamimetics used are preferably com 1-, 2-, 3- or 4-substituted by a group R, pounds selected from among arformoterol, carmoterol, for 0036 and moterol, indacaterol, salmeterol, albuterol, bambuterol, 0037 R which may be identical or different, denotes bitolterol, broXaterol, carbuterol, clenbuterol, fenoterol, hydrogen, or hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalb 0038 a group selected from among OH, C-C- utamol, mabuterol, meluadrine, metaproterenol, milveterol, alkyl and —O-C-C-alkyl orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, optionally in the form of the tautomers, the racemates, the ritodrine, Salmefamol, Soterenol, Sulphonterol, terbutaline, enantiomers, the diastereomers and the mixtures thereof, and tiaramide, tolubuterol, Zinterol and optionally the pharmacologically acceptable acid addition 0052 6-hydroxy-8-1-hydroxy-2-[2-(4-methoxy-phe salts thereof, and the solvates and hydrates thereof. nyl)-1,1-dimethyl-ethylamino-ethyl-4H-benzo[1,4]ox 0039. Preferred compounds of formula (I) are those azin-3-one wherein 0053 8-2-[2-(2,4-difluoro-phenyl)-1,1-dimethyl-ethy 0040) R' denotes a group selected from among lamino-1-hydroxy-ethyl-6-hydroxy-4H-benzo[1,4]ox 3-chloro-2-fluoro-phenyl, 3-chloro-4-fluoro-phenyl, azin-3-one 5-chloro-2-fluoro-phenyl, 2-fluoro-3-methyl-phenyl, 0054 8-2-[2-(3,5-difluoro-phenyl)-1,1-dimethyl-ethy
Recommended publications
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • Prohibited Antibiotics, Hormones and Other Chemicals) Regulations 2012

    Prohibited Antibiotics, Hormones and Other Chemicals) Regulations 2012

    WARTA KERAJAAN PERSEKUTUAN FEDERAL GOVERNMENT 29 Ogos 2012 GAZETTE 29 August 2012 P.U. (A) 272 PERATURAN-PERATURAN MAKANAN HAIWAN (ANTIBIOTIK, HORMON DAN BAHAN KIMIA LAIN TERLARANG) 2012 FEED (PROHIBITED ANTIBIOTICS, HORMONES AND OTHER CHEMICALS) REGULATIONS 2012 DISIARKAN OLEH/ PUBLISHED BY JABATAN PEGUAM NEGARA/ ATTORNEY GENERAL’S CHAMBERS P.U. (A) 272 AKTA MAKANAN HAIWAN 2009 PERATURAN-PERATURAN MAKANAN HAIWAN (ANTIBIOTIK, HORMON DAN BAHAN KIMIA LAIN TERLARANG) 2012 PADA menjalankan kuasa yang diberikan oleh perenggan 53(2)(f) Akta Makanan Haiwan 2009 [Akta 698], Menteri, setelah berunding dengan Lembaga, membuat peraturan-peraturan yang berikut: Nama 1. Peraturan-peraturan ini bolehlah dinamakan Peraturan-Peraturan Makanan Haiwan (Antibiotik, Hormon dan Bahan Kimia Lain Terlarang) 2012. Tafsiran 2. Dalam Peraturan-Peraturan ini, melainkan jika konteksnya menghendaki makna yang lain, “haiwan penghasil makanan” ertinya mana-mana haiwan yang diberi makan untuk tujuan penghasilan makanan bagi kegunaan manusia. Antibiotik, hormon dan bahan kimia lain terlarang 3. (1) Penggunaan antibiotik, hormon dan bahan kimia lain dalam makanan haiwan dan bahan tambahan makanan haiwan bagi kategori haiwan sebagaimana yang ditetapkan dalam Jadual, adalah dilarang. (2) Mana-mana orang yang melanggar subperaturan (1) melakukan suatu kesalahan dan boleh, apabila disabitkan, didenda tidak melebihi sepuluh ribu ringgit atau dipenjarakan selama tempoh tidak melebihi dua tahun atau kedua-duanya. 2 P.U. (A) 272 JADUAL JAMH 53(2)(f)01 [subperaturan 3(1)] ANTIBIOTIK, HORMON DAN BAHAN KIMIA LAIN TERLARANG A. Antibiotik Antibiotik Larangan (a) Avoparcin Penggunaan dalam makanan haiwan dan bahan tambahan makanan haiwan untuk semua haiwan (a) Kloramfenikol Penggunaan dalam makanan haiwan dan bahan (b) Nitrofurans: tambahan makanan haiwan untuk haiwan penghasil (i) Nitrofurantoin makanan (ii) Nitrofurazon (iii) Furazolidone (iv) Furaltadone (c) Teicoplanin (d) Vankomisin (e) Carbadox (f) Olaquindox B.
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub

    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr

    (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr

    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
  • 2 11/ 7 361Al

    2 11/ 7 361Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date - l 6 June 20ll (I6.06.20ll) 2 11/ 7 361 Al (51) International Patent Classification: (74) Agents: KINNAIRD, James et al; 90 High Holborn, A61K 9/14 (2006.01) A61K 9/51 (2006.01) London, Greater London WC1V 6XX (GB). A61K 9/16 (2006.01) A61K 31/4045 (2006.01) (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, PCT/GB2010/052053 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 8 December 2010 (08.12.2010) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (25) Filing Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (30) Priority Data: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 0921481 .8 8 December 2009 (08.12.2009) GB (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): VEC- kind of regional protection available): ARIPO (BW, GH, TURA LIMITED [—/GB]; 1 Prospect West, Chippen GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ham Wiltshire SN14 6FH (GB).
  • (12) United States Patent (10) Patent No.: US 6,250,300 B1 Andersson Et Al

    (12) United States Patent (10) Patent No.: US 6,250,300 B1 Andersson Et Al

    USOO6250300B1 (12) United States Patent (10) Patent No.: US 6,250,300 B1 Andersson et al. (45) Date of Patent: Jun. 26, 2001 (54) SYSTEM FOR DISPENSING FOREIGN PATENT DOCUMENTS PHARMACEUTICALLY ACTIVE 0 069 715 6/1982 (EP). COMPOUNDS O 237 507 2/1987 (EP). O530440 6/1992 (EP). (75) Inventors: Jan Andersson, Sodra Sandby; Hans WO 90/13328 11/1990 (WO). Jägfäldt; Eva Trofast, both of Lund; WO 92/04069 3/1992 (WO). Kjell Wetterlin, Sodra Sandby, all of WO 93/17728 9/1993 (WO). (SE) OTHER PUBLICATIONS (73) Assignee: AB Astra, Sodertalje (SE) Bogaard et al., Dose-effect Relationship of Terbutaline (*) Notice: Subject to any disclaimer, the term of this Using a Multi-dose Power Inhalation System patent is extended or adjusted under 35 (Turbuhaler) ... Powder Inhalation (Rotahaler) in Asth U.S.C. 154(b) by 0 days. matics, Pharmatherapeutica 5:400-406, 1989. Tukiainen and Terho, Comparison of Inhaled Salbutamol (21) Appl. No.: 09/418,342 Powder and Aerosol in Asthmatic Patients with Low Peak Expiratory Flow Level, Eur. J. Clin. Pharmacol. (22) Filed: Oct. 14, 1999 27:645-647, 1985. Related U.S. Application Data (List continued on next page.) (62) Division of application No. 09/309,039, filed on May 10, 1999, which is a continuation of application No. 08/866,749, Primary Examiner-Glenn K. Dawson filed on May 30, 1997, now Pat. No. 5,934,273, which is a ASSistant Examiner V. Srivastava continuation of application No. 08/654,006, filed on May 29, (74) Attorney, Agent, or Firm-Fish & Richardson P.C.
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al

    US 20100184806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow et al. (43) Pub. Date: Jul. 22, 2010 (54) MODULATION OF NEUROGENESIS BY PPAR (60) Provisional application No. 60/826,206, filed on Sep. AGENTS 19, 2006. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); Todd Carter, San Diego, CA Publication Classification (US); Andrew Morse, San Diego, (51) Int. Cl. CA (US); Kai Treuner, San Diego, A6II 3/4433 (2006.01) CA (US); Kym Lorrain, San A6II 3/4439 (2006.01) Diego, CA (US) A6IP 25/00 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) SUGHRUE MION, PLLC A6IP 25/22 (2006.01) 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (52) U.S. Cl. ......................................... 514/337; 514/342 WASHINGTON, DC 20037 (US) (57) ABSTRACT (73) Assignee: BrainCells, Inc., San Diego, CA (US) The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system (21) Appl. No.: 12/690,915 including by stimulating or increasing neurogenesis, neuro proliferation, and/or neurodifferentiation. The disclosure (22) Filed: Jan. 20, 2010 includes compositions and methods based on use of a peroxi some proliferator-activated receptor (PPAR) agent, option Related U.S. Application Data ally in combination with one or more neurogenic agents, to (63) Continuation-in-part of application No. 1 1/857,221, stimulate or increase a neurogenic response and/or to treat a filed on Sep. 18, 2007. nervous system disease or disorder. Patent Application Publication Jul. 22, 2010 Sheet 1 of 9 US 2010/O184806 A1 Figure 1: Human Neurogenesis Assay Ciprofibrate Neuronal Differentiation (TUJ1) 100 8090 Ciprofibrates 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 Conc(M) Patent Application Publication Jul.